This product is an ASHP Learning Center https://elearning.ashp.org/ activity.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Target Audience
The Specialty Pharmacy: Hematologic Disorders Certificate is self-guided, with online learning activities that have been created for pharmacists seeking to expand their skills in specialty pharmacy management of hematologic disorders.
Overview
The Specialty Pharmacy Certificate is self-guided, with online learning activities that have been created for pharmacists seeking to expand their skills in specialty pharmacy.
A learner will have completed the Specialty Pharmacy Fundamentals before beginning the Hematologic Disorders Track.
The learner will then take a deep dive into their selected specialty focus with the Hematologic Disorders Track. These topics include hemophilia A and B, von Willebrand Disease, rare factor disorders, thrombotic thrombocytopenic purpura, and congenital plasminogen deficiency.
Specialty Pharmacy: Hematologic Disorders Professional Certificate Requirement
Once a learner has completed the Specialty Pharmacy Fundamentals and the Hematologic Disorders Track educational curriculum, they will have the opportunity to complete the track’s final exam. Once the learner successfully completes the track’s final exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the Specialty Pharmacy: Hematologic Disorders Professional Certificate.
Educational Activities
Specialty Pharmacy: Hematologic Disorders Track
Hemophilia A
ACPE: 0204-0000-25-880-H01-P
Application-based
2.75 contact hours
Learning Objectives:
- Identify hemophilia disease severity based on laboratory results.
- Contrast the presentation and treatment of congenital and acquired hemophilia.
- Modify a FVIII prophylaxis regimen using pharmacokinetic results.
- Calculate emicizumab loading and maintenance dosing.
- Counsel a patient on the administration and monitoring of desmopressin.
- Develop a treatment plan for a hemophilia A patient with inhibitors.
Hemophilia B
ACPE: 0204-0000-25-881-H01-P
Application-based
2.5 contact hours
Learning Objectives:
- Identify the genetic inheritance of Hemophilia B.
- Compare different severities of Hemophilia B.
- Differentiate available FIX products.
- Identify novel treatment options.
- Choose an appropriate treatment regimen.
- Assess a treatment plan for Hemophilia B patients.
- Describe the healthcare cost associated with Hemophilia B.
Von Willebrand Disease
ACPE: 0204-0000-25-882-H01-P
Application-based
2 contact hours
Learning Objectives:
- Describe the functions of the von Willebrand factor.
- Summarize the pathophysiology of von Willebrand disease (vWD).
- Differentiate the types of vWD.
- Identify the laboratory tests used to evaluate vWD.
- Assess methods of diagnosis and diagnostic challenges.
- Differentiate the treatment options for a patient with vWD.
- Evaluate the role of the pharmacist in managing patients with vWD.
Rare Factor Disorders
ACPE: 0204-0000-25-883-H01-P
Application-based
1.75 contact hours
Learning Objectives:
- Evaluate PT/PTT levels in relation to the clotting cascade and factor deficiencies.
- Differentiate the subtypes of FI disorders.
- Recommend a dose of prothrombin complex concentrate for a patient with FII disorder.
- Apply knowledge of FVII levels and symptoms when determining treatment needs in patients with FVII disorders.
- Choose medication therapy for a patient with FXI deficiency undergoing surgery.
- Contrast the available clotting factor medications available for patients with FXIII deficiency.
Thrombotic Thrombocytopenic Purpura & Congenital Plasminogen Deficiency
ACPE: 0204-0000-25-884-H01-P
Application-based
1 contact hour
Learning Objectives:
- Describe the pathophysiology, clinical presentation, and diagnosis of congenital and acquired TTP.
- Compare the current treatment modalities available for congenital and acquired TTP.
- Analyze clinical practice guidelines for the management of congenital and acquired TTP.
- Describe congential plasminogen deficiency.
Faculty Information
Lauren Campanella, PharmD, BCOP
Clinical Pharmacist
St. Joseph’s Hospital for Bleeding and Clotting Disorders
Tampa, Florida
Kathryn Dane, PharmD, BCPS
Clinical Pharmacy Specialist, Benign Hematology and Cardiology
Co-Director, Hemostatic and Antithrombotic Stewardship Program
The Johns Hopkins Hospital
Baltimore, Maryland
Katie Rasmussen, PharmD, BCPPS
Clinical Pharmacy Specialist
Prisma Health Children’s Hospital
Hemophilia Treatment Center of South Carolina
Columbus, South Carolina
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
- Lauren Campanella: Sanofi - Consultant Advisor; Novo Nordisk, Speaker's Bureau
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Methods and CE Requirements
Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Important Note – ACPE 60 Day Deadline:
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP eProfile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.
The ASHP Professional Certificates SM educational product line contains learning activities that are ACPE-accredited knowledge and application-based continuing education. This is not an ACPE Certificate Program. Upon successful completion of the activities, the learner will be able to download an ASHP Professional Certificate.
System Technical Requirements
ASHP learning content is delivered through your Web browser. For all learning content, you will need basic computer skills, the ability to navigate web pages and stable internet connection. View the system requirements for learning activities.